Abstract
Onchocerciasis is a major blinding disease affecting at least 28 million people in Africa and Latin America. Although a large-scale vector control program has been highly successful in limiting transmission of infection in West Africa, there has not been a satisfactory form of treatment available for those already infected or those living in other areas. Despite the fact that two drugs, diethylcarbamazine and suramin, are active against the filarial parasite that causes onchocerciasis, their use is severely limited by their toxicity and the reaction they induce. A newly developed drug, ivermectin, appears to offer a major revolution in the treatment of onchocerciasis. In a series of clinical trials, ivermectin has been shown to be an extremely effective microfilaricide which induces only minimal side effects. Ivermectin is given as a single oral dose which can be repeated on an annual basis. In view of its safety and efficacy and its ease of administration, it seems likely that ivermectin will be suitable for use in mass chemotherapy programs against onchocerciasis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Awadzi K, Dadzie KY, Schulz-Key H, Haddock DRW, Gilles HM, Aziz MA. The chemotherapy of onchocerciasis X. An assessment of four single dose treatment regimes of MK-933 (ivermectin) in human onchocerciasis. Ann Trop Med Parasitol 1985; 79: 63–78.
Aziz MA, Diallo S, Diop IM, Lariviere M. Efficacy and tolerance of ivermectin in human onchocerciasis. Lancet 1982; 2: 171–73.
Bland gnJ. A decade of oncho control. World Health 1985; October: 1–27.
Campbell WC, Fisher MH, Stapley EO, Albers-Schonberg G, Jacob TA. Ivermectin: A potent new antiparasitic agent. Science 1983; 221: 823–28.
Cupp EW, Bernardo MJ, Kiszewski AE, Collins RC, Taylor HR, Aziz MA, Greene BM. The effects of ivermectin ontransmission of Onchocerca volvulus. Science 1986; 231: 740–42.
Greene BM, Taylor HR, Cupp EW, Murphy RP, White AT, Aziz MA, Schulz-Key H, D'Anna SA, Newland HS, Goldschmidt LP, Auer C, Hanson AP, Freeman SV, Reber EW, Williams PN. Comparison of ivermectin and diethyl-carbamazine in the treatment of onchocerciasis. N Engl J Med 1985; 313: 133–38.
Lariviere M, Vingtain P, Aziz M, Beauvais B, Weimann D, Derouin F, Schulz-Key H, Barret D, Sarfati D Double-blind study of ivermectin and diethylcarbamazine in African onchocerciasis patients with ocular involvement. Lancet: 1985; 2: 174–77.
Prost A, Vaugelade J. La surmortalite des aveugles en zonede Savane Ouest-Africaine. Bull WHO 1981; 59: 773–76.
Taylor HR. Recent developments in the treatment of onchocerciasis. Bull WHO 1984; 62: 509–15.
Taylor HR, Dax EM, Ocular onchocerciasis, chapter 41. Infections of the Eye. Boston: Little, Brown and Company, 1986; 53–564.
Taylor HR, Murphy RP, Newland HS, White AT, D'Anna SA, Keyvan-Larijani E, Aziz MA, Cupp EW, Greene BM. Comparison of the treatment of ocular onchocerciasis with ivermectin and diethylcarbamazine. Arch Ophthalmol 1986; 104: 863–70.
Author information
Authors and Affiliations
Additional information
Supported in part by a grant from the World Health Organization Onchocerciasis Chemotherapy Project of the Onchocerciasis Control Programme in the Volta River Basin Area (Research Proposal No. 84021).
Rights and permissions
About this article
Cite this article
Taylor, H.R. Onchocerciasis — A potential revolution in its treatment. Int Ophthalmol 11, 83–85 (1987). https://doi.org/10.1007/BF00136735
Issue Date:
DOI: https://doi.org/10.1007/BF00136735